Harry Ahdieh - Concepedia

Author

Harry Ahdieh

Endo Pharmaceuticals (United States)

Also Known As

Ahdieh, harry, Dart, Richard, Harry Ahdieh, Harry Ahdieh, PhD, Harry B Ahdieh, Harry B. Ahdieh

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Endo Pharmaceuticals (United States)Rutgers, The State University of New Jersey Arizona Research Center Carolinas Pain Institute City Of Hope National Medical Center

About

Harry Ahdieh is an author at Endo Pharmaceuticals (United States) specializing in medicine, physiology, and endocrinology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	672
2	Health Sciences	7	7	401
3	Public Health	3	3	81
4	Anesthesia	2	2	70
5	Social Sciences	1	1	35

Harry Ahdieh

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of OPANA ER (Oxymorphone Extended Release) for Relief of Moderate to Severe Chronic Low Back Pain in Opioid-Experienced Patients: A 12-Week, Randomized, Double-blind, Placebo-controlled Study M. Hale, Harry Ahdieh, Tina Ma, Journal of Pain Pain TherapyPain ResearchHealth SciencesOxymorphone Extended ReleasePain Medicine	2006	168
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain Nathaniel P. Katz, Richard Rauck, Harry Ahdieh, Current Medical Research and Opinion	2006	136
Oxymorphone Extended-Release Tablets Relieve Moderate to Severe Pain and Improve Physical Function in Osteoarthritis: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Trial Alan K. Matsumoto, Najib Babul, Harry Ahdieh Pain Medicine	2005	118
A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee Alan Kivitz, Carl Ma, Harry Ahdieh, Clinical Therapeutics Pain MedicinePhase Iii TrialChronic Musculoskeletal ConditionOsteoarthritisOrthopaedics	2006	82
Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study Nashat Gabrail, Chris Dvergsten, Harry Ahdieh Current Medical Research and Opinion	2004	79
Oxymorphone Extended Release Does Not Affect CYP2C9 or CYP3A4 Metabolic Pathways Michael P. Adams, Henry J. Pieniaszek, Arnold R. Gammaitoni, The Journal of Clinical Pharmacology Healthy SubjectsPharmacotherapyExperimental PharmacologyDrug ResistanceMolecular Pharmacology	2005	70
Pharmacokinetics and Dose‐Proportionality of Oxymorphone Extended Release and Its Metabolites: Results of a Randomized Crossover Study Michael P. Adams, Harry Ahdieh Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2004	65
Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study Paul A. Sloan, Neal E. Slatkin, Harry Ahdieh Supportive Care in Cancer Pilot StudyHealth SciencesPain MedicineMedicinePharmacology	2004	62
Safety, Tolerability, and Effectiveness of Oxymorphone Extended Release for Moderate to Severe Osteoarthritis Pain Harris McIlwain, Harry Ahdieh American Journal of Therapeutics	2005	62
The Efficacy and Safety of Oral Immediate-Release Oxymorphone for Postsurgical Pain Joseph Gimbel, Harry Ahdieh Anesthesia & Analgesia	2004	51

Page 1